Category: Aspirin

Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.

Aspirin, Cardiology, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

After percutaneous coronary intervention (PCI) with second-generation drug-eluting stent (DES), whether short dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT) with a P2Y12 receptor inhibitor confers benefits compared […]

» Read more

Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) after Percutaneous Coronary Intervention in High-Risk Patients with Diabetes Mellitus.

Aspirin, Cardiology, Cardiology Guidelines, Clopidogrel, Diabetes, Guidelines for the Treatment & Management of Myocardial infarction, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

The efficacy and safety of prolonged (>1-year) dual antiplatelet therapy (DAPT) duration in high-risk patients with diabetes mellitus (DM) undergoing PCI remain unknown. All patients undergoing PCI at Fuwai hospital […]

» Read more

Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence.

Aspirin, Cardiology, Cardiology Guidelines, Interventional Cardiology, Preventative Cardiology
Bookmark this %label%

Aspirin has been the mainstay of both secondary and primary prevention of cardiovascular disease for half a century. In 2018, 3 trials showed a modest reduction in cardiovascular outcomes that […]

» Read more

Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.

Aspirin, Cardiology, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST […]

» Read more

Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).

Aspirin, Cardiology, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

Patients undergoing staged percutaneous coronary intervention (SPCI) are exposed to extended duration of antiplatelet therapy, and a novel aspirin-free antiplatelet regimen after SPCI should be specifically evaluated among these patients. […]

» Read more

Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (From a Nationwide Healthcare System).

Aspirin, Cardiology, Cardiology Guidelines, Preventative Cardiology
Bookmark this %label%

The American College of Cardiology and American Heart Association recently published guidelines narrowing the indications for low-dose aspirin use. The suitability of the electronic health record (EHR) to identify patients […]

» Read more

Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention.

Aspirin, Cardiology, Cardiology Guidelines, Guidelines for the Treatment & Management of Myocardial infarction, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

Dual antiplatelet therapy (DAPT) reduces ischemic and thrombotic events after percutaneous coronary intervention (PCI). Initial reports of higher myocardial infarction and mortality rates prompted guideline committees to choose 12-month duration […]

» Read more

Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.

Aspirin, Atrial fibrillation, Cardiology, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

To compare the safety and efficacy of edoxaban combined with P2Y12 inhibition following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome (ACS) […]

» Read more

Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.

Aspirin, Cardiology, Clopidogrel, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

Patients who underwent complex percutaneous coronary intervention (PCI) are known to be at high risk for both ischemic and bleeding complications. The risk/benefit tradeoff of extending dual antiplatelet therapy (DAPT) […]

» Read more

Effect of Ticagrelor on Reducing the Risk of Gram-Positive Infections in Patients With Acute Coronary Syndrome.

Aspirin, Cardiology, Clopidogrel
Bookmark this %label%

In light of recent studies describing the antibacterial properties of ticagrelor, the association between treatment with ticagrelor and subsequent risk for infection following acute coronary syndrome (ACS) is taking on […]

» Read more

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.

Aspirin, Cardiology, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute […]

» Read more

Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome.

Aspirin, Cardiology, Cardiology Guidelines, Clopidogrel, Guidelines for the Treatment & Management of Myocardial infarction, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

Dual antiplatelet therapy combining aspirin with a P2Y12-receptor inhibitor reduces atherothrombotic events following an acute coronary syndromes (ACS), but the relative merits of different P2Y12 inhibitors remain unclear, despite several […]

» Read more

Acute recurrent pericarditis: from pathophysiology towards new treatment strategy.

Aspirin, Cardiology, Cardiology Guidelines, Guidelines for the Treatment & Management of Pericarditis, Pericarditis
Bookmark this %label%

Acute idiopathic or so-called viral pericarditis is a frequent and usually benign disease, although recurrences are frequent. Data strongly suggest the presence of underlying autoinflammatory and/or autoimmune disorders. It has […]

» Read more

Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor.

Aspirin, Cardiology, Clopidogrel
Bookmark this %label%

Intraocular bleeding is a devastating clinical event due to its potentially blinding nature. It is not known if determine if dual antiplatelet therapy using aspirin and potent P2Y12 inhibitors increases […]

» Read more

P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis.

Aspirin, Atrial fibrillation, Cardiology, Clopidogrel, Interventional Cardiology
Bookmark this %label%

This study aimed to compare the safety and efficacy of third-generation P2Y12 inhibitors versus clopidogrel in combination with oral anticoagulation (OAC) with or without aspirin in patients with atrial fibrillation […]

» Read more

Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).

Aspirin, Atrial fibrillation, Cardiology, Clopidogrel, Interventional Cardiology, Warfarin
Bookmark this %label%

The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or […]

» Read more

Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa.

Aspirin, Cardiology, Myocardial infarction
Bookmark this %label%

Platelet expression of FcγRIIa was quantified after myocardial infarction (MI) and we found that patients with high platelet FcγRIIa expression (>11,000/platelet) had a fourfold greater risk of subsequent MI, stroke, […]

» Read more

Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.

Aspirin, Cardiology, Interventional Cardiology, Myocardial infarction, Preventative Cardiology
Bookmark this %label%

PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with an acceptable increase in bleeding, in patients […]

» Read more

Relation of Hypoalbuminemia to Response to Aspirin in Patients With Stable Coronary Artery Disease.

Aspirin, Cardiology
Bookmark this %label%

Serum albumin (SA) level is a powerful cardiovascular prognostic marker, suggested to be involved in regulation of platelet function. High on-aspirin platelet reactivity (HAPR) is associated with increased risk for […]

» Read more

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.

Aspirin, Cardiology, Clopidogrel, Preventative Cardiology
Bookmark this %label%

Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) […]

» Read more

Effectiveness of Only Aspirin or Clopidogrel Following Percutaneous Left Atrial Appendage Closure.

Aspirin, Atrial fibrillation, Cardiology, Clopidogrel, Preventative Cardiology
Bookmark this %label%

Percutaneous left atrial appendage closure (LAAC) offers a feasible option for stroke prevention in patients with atrial fibrillation (AF), but the optimal antithrombotic treatment strategy for patients with strict contraindications […]

» Read more

Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry).

Aspirin, Cardiology, Cardiology Guidelines, Clopidogrel, Diabetes, Guidelines for the Treatment & Management of Heart failure, Guidelines for the Treatment & Management of Hypertension, Guidelines for the Treatment & Management of Myocardial infarction, Heart failure, Hypertension, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

The use of prasugrel and ticagrelor as part of dual antiplatelet therapy is increasing in patients after percutaneous coronary intervention (PCI). Accordingly, we aimed to evaluate their prescription patterns in […]

» Read more

Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study).

Aspirin, Cardiology, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

The risk of major adverse cardiac and cerebrovascular events (MACCE) in subjects who interrupt temporarily or permanently thienopyridine therapy in the first 6 months after percutaneous coronary intervention (PCI) remains […]

» Read more

Usefulness of Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease.

Aspirin, Cardiology, Preventative Cardiology
Bookmark this %label%

Abstract: Aspirin use in the prevention of cardiovascular events has been a mainstay of treatment for decades. However, the use of aspirin in primary prevention of atherosclerotic cardiovascular disease has […]

» Read more

Ticagrelor with or without Aspirin in High-Risk Patients after PCI.

Aspirin, Cardiology, Interventional Cardiology, Myocardial infarction
Bookmark this %label%

Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI).In a double-blind […]

» Read more
1 2